DRMA יחס מהיר Dermata Therapeutics

Serving as confirmation of the market valuation, the price action chart on the GURU.Markets platform helps analyze the resilience of Dermata Therapeutics (DRMA) to macroeconomic shocks, as the treatment of skin pathologies is non-cyclical. The business is protected by costly patents for active substance delivery methods that require massive investments. The current metric stands at 2.67, while the company remains in the testing phase, which eliminates operating leverage and leads to a proportional increase in costs.

The ratio is calculated by dividing liquid assets, minus inventory, by current liabilities. This metric determines the company's ability to immediately settle debts without relying on the sale of inventory. For Dermata Therapeutics (DRMA), this is critical while awaiting insurance reimbursements for innovative acne medications. The current value of 2.67 on the quick ratio chart reflects the business's real-time financial strength.